Comparison of first- and second-generation drug-eluting stents in an all-comer population of patients with diabetes mellitus (from Katowice-Zabrze Registry)

Medical Science Monitor

Volumn 21, Issue , 2015, Pages 3261-3269

  Kawecki, Damian ^a   Morawiec, Beata ^a   Dola, Janusz ^a   Wańha, Wojciech ^a   Smolka, Grzegorz ^a   Pluta, Aleksandra ^a   Marcinkiewicz, Kamil ^a   Ochała, Andrzej ^a   Nowalany Kozielska, Ewa ^a   Wojakowski, Wojciech ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Coronary thrombosis; Diabetes mellitus; Drug eluting stents; Percutaneous coronary intervention

Indexed keywords

EVEROLIMUS; FIBRINOGEN RECEPTOR ANTAGONIST; PACLITAXEL; RAPAMYCIN; TROPONIN; UMIROLIMUS; ZOTAROLIMUS;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BIOLIMUS ELUTING CORONARY STENT; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; CORONARY ARTERY BYPASS GRAFT; DEATH; DEVICE SAFETY; DIABETES MELLITUS; DRUG ELUTING STENT; EVEROLIMUS ELUTING CORONARY STENT; FEMALE; HAZARD RATIO; HEART MUSCLE REVASCULARIZATION; HUMAN; INTRAVASCULAR ULTRASOUND; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PACLITAXEL ELUTING CORONARY STENT; PERCUTANEOUS CORONARY INTERVENTION; SIROLIMUS ELUTING CORONARY STENT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; SYNTAX SCORE; UNSTABLE ANGINA PECTORIS; ZOTAROLIMUS ELUTING CORONARY STENT; ANALOGS AND DERIVATIVES; ANGIOGRAPHY; CHEMICALLY INDUCED; CLINICAL TRIAL; CORONARY STENOSIS; FOLLOW UP; HEART INFARCTION; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; POLAND; PROPORTIONAL HAZARDS MODEL; REGISTER; RETROSPECTIVE STUDY; STENT; THROMBOSIS; TREATMENT OUTCOME;

AGED; ANGIOGRAPHY; CORONARY STENOSIS; DIABETES MELLITUS; DRUG-ELUTING STENTS; EVEROLIMUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PACLITAXEL; PERCUTANEOUS CORONARY INTERVENTION; POLAND; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; SIROLIMUS; STENTS; THROMBOSIS; TREATMENT OUTCOME;

EID: 84945922011     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.895095     Document Type: Article

References (31)

1. Mathew V, Holmes DR: Outcomes in diabetics undergoing revascularization: the long and the short of it. J Am Coll Cardiol, 2002; 40: 424-27
2. Van Belle E, Perie M, Braune D et al: Effects of coronary stenting on vessel patency and long-term clinical outcome after percutaneous coronary revascularization in diabetic patients. J Am Coll Cardiol, 2002; 40: 410-17
3. Smith SC Jr, Faxon D, Cascio W et al: Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group VI: revascularization in diabetic patients. Circulation, 2002; 105(18): e165-69
4. Mohr FW, Morice MC, Kappetein A et al: Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet, 2013; 381: 629-38
5. Farkouh ME, Domanski M, Sleeper LA et al., FREEDOM Trial Investigators: Strategies for multivessel revascularization in patients with diabetes. N Engl J Med, 2012; 367: 2375-84
6. Di Lorenzo E, Sauro R, Varricchio A et al: Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs. bare metal stent in primary angiOplasty (PASEO) randomized trial. Am Heart J, 2009; 158(4): e43-50
7. Kirtane AJ, Ellis SG, Dawkins KD et al: Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials. J Am Coll Cardiol, 2008; 51: 708-15
8. Sinning JM, Baumgart D, Werner N et al., SCORPIUS Study: Five-year results of the multicenter randomized controlled open-label study of the CYPHER sirolimus-eluting stent in the treatment of diabetic patients with de novo native coronary artery lesions (SCORPIUS) study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. Am Heart J, 2012; 163: 446-453, 453.e1
9. Briguori C, Airoldi F, Visconti G et al: Novel approaches for preventing or limiting events in diabetic patients (NAPLES-DIABETES) trial: a randomized comparison of 3 drug-eluting stents in diabetic patients. Circ Cardiovasc Interv, 2011; 4: 121-29
10. Cassese S, Byrne RA, Tada T et al: Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. Heart, 2014; 100(2): 153-59
11. Bangalore S, Toklu B, Feit F: Outcomes with coronary artery bypass graft surgery versus percutaneous coronary intervention for patients with diabetes mellitus can newer generation drug-eluting stents bridge the gap? Circ Cardiovasc Interv, 2014; 7: 518-25
12. Thygesen K, Alpert JS, Jaffe AS et al., Writing Group on the Joint ESC/ACCF/ AHA/WHF Task Force for the Universal Definition of Myocardial Infarction: Third universal definition of myocardial infarction. Eur Heart J, 2012; 33: 2551-67
13. Cutlip DE, Windecker S, Mehran R et al., Academic Research Consortium: Clinical end points in coronary stent trials: a case for standardized definitions. Circulation, 2007; 115: 2344-51
14. Mehran R, Rao SV, Bhatt DL et al: Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation, 2011; 123: 2736-47
15. Yagi H, Amiya E, AndoIn J et al: Stent restenosis exacerbated by drug-induced severe eosinophilia after second-generation drug-eluting stent implantation. Am J Case Rep, 2014; 15: 397-400
16. Armstron EJ, Rutledge JC, Rogers JH: Coronary artery revascularization in patients with diabetes mellitus. Circulation, 2013; 128: 1675-85
17. Stone GW, Midei M, Newman M et al., SPIRIT III Investigators: Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA, 2008; 299(16): 1903-13
18. Grube E, Chevalier B, Guagliumi G et al: The SPIRIT V diabetic study: a randomized clinical evaluation of the XIENCE V everolimus-eluting stent vs. the TAXUS Liberté paclitaxel-eluting stent in diabetic patients with de novo coronary artery lesions. Am Heart J, 2012; 163: 867-875.e1
19. Otake H, Ako J, Yamasaki M et al: Comparison of everolimus-versus paclitaxel-eluting stents implanted in patients with diabetes mellitus as evaluated by three-dimensional intravascular ultrasound analysis. Am J Cardiol, 2010; 106: 492-97
20. Kim WJ, Lee SW, Park SW et al., ESSENCE-DIABETES Study Investigators: Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial. Circulation, 2011; 124: 886-92
21. Simsek C, Räber L, Magro M et al: Long-term outcome of the unrestricted use of everolimus-eluting stents compared to sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients: The Bern-Rotterdam diabetes cohort study. Int J Cardiol, 2013; 170: 36-42
22. Stone GW, Kedhi E, Kereiakes DJ et al: Differential clinical responses to everolimus-eluting and paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation, 2011; 124: 893-900
23. Kereiakes DJ, Cutlip DE, Applegate RJ et al: Outcomes in diabetic and nondiabetic patients treated with everolimus-or paclitaxel-eluting stents results from the SPIRIT IV clinical trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system). J Am Coll Cardiol, 2010; 56: 2084-89
24. Haffner SM, Lehto S, Ronnemaa T et al: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 1998; 339: 229-34
25. Kedhi E, Généreux P, Palmerini T et al: Impact of coronary lesion complexity on drug-eluting stent outcomes in patients with and without diabetes mellitus analysis from 18 pooled randomized trials. J Am Coll Cardiol, 2014; 63: 2111-18
26. Jensen LO, Thayssen P, Junker A et al: Comparison of outcomes in patients with versus without diabetes mellitus after revascularization with everolimus-and sirolimus-eluting stents (from the SORT OUT IV trial). Am J Cardiol, 2012; 110(11): 1585-91
27. Bangalore S, Kumar S, Fusaro M et al: Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomized trials. BMJ, 2012; 345: e5170
28. D'Amico G, Fabris T, Mojoli M et al: Impact of drug-eluting stent generation on patient-and stent-related adverse events of diabetic patients treated by percutaneous coronary intervention. Minerva Cardioangiol, 2014; 62(1): 9-18
29. Jensen LO, Thayssen P, Junker A et al: Comparison of outcomes in patients with versus without diabetes mellitus after revascularization with everolimus-and sirolimus-eluting stents (from the SORT OUT IV Trial). Am J Cardiol, 2012; 110: 1585-91
30. Maeng M, Jensen LO, Tilsted HH et al: Outcomes of sirolimus-eluting versus zotarolimus-eluting coronary stent implantation in patients with and without diabetes mellitus (a SORT OUT III substudy). Am J Cardiol, 2011; 108: 1232-37
31. Yan P, Dong P, Li Z: Second-versus first-generation drug-eluting stents for diabetic patients: a meta-analysis. Arch Med Sci, 2014; 10(2): 213-21